AVNS Q1 2024: Digestive Health Delivers 9% Organic Growth, Margin Expansion Signals Transformation Traction
AVNS’s transformation strategy delivered visible progress in Q1, with digestive health posting standout growth and margin expansion outpacing expectations. Pain management recovery remains a work in progress, but operational discipline and portfolio focus are yielding measurable financial improvements. Management’s confidence in mid-term targets is underpinned by robust execution, cost control, and a clear capital allocation agenda.
Summary
- Digestive Health Outpaces Market: Neomid and legacy enteral feeding drive above-market growth as portfolio rationalization unlocks margin gains.
- Pain Management Stabilizes: Segment progress is uneven but new product traction and ASC channel execution support 2024 growth targets.
- Margin Expansion Accelerates: Transformation initiatives drive cost leverage and position AVNS for further profitability improvements into 2025.
Business Overview
AVNS (Avanos Medical) is a medical device company focused on digestive health (enteral feeding, Neomid, and related products) and pain management and recovery (surgical pain, radiofrequency ablation, and Game Ready). AVNS generates revenue by selling devices and consumables to hospitals, ambulatory surgery centers (ASCs), and distributors, with its business split between digestive health (a growth engine) and pain management (in transformation). The company is actively reshaping its portfolio through product exits, M&A, and cost discipline to drive growth and margin expansion.
Performance Analysis
AVNS’s Q1 results demonstrate tangible progress in both growth and profitability, anchored by a strong performance in digestive health. The segment, led by Neomid, delivered double-digit growth, capitalizing on continued NFIT (Nasogastric Feeding Tube) adoption in North America, while legacy enteral feeding grew mid-single digits. This momentum validates the company’s focus on innovation and targeted market expansion.
Conversely, pain management and recovery posted a slight year-over-year decline (down 1% ex-divestitures and FX), but management points to stabilization and new product contributions, especially from the Trident line and Game Ready, which achieved double-digit growth. Gross margin expanded nearly 300 basis points year-over-year (approaching 60%), reflecting disciplined product rationalization, manufacturing execution, and SG&A optimization. SG&A leverage improved by over 200 basis points, supporting a 34% jump in adjusted EBITDA and a 69% rise in adjusted diluted EPS.
- Digestive Health Drives Top-Line: Neomid and enteral feeding outperformed, offsetting anticipated headwinds in HA (hyaluronic acid) products.
- Pain Portfolio Mixed: RF ablation and Game Ready show traction, but IV infusion and needle kits/trays underperformed.
- Transformation Yields Margin Leverage: Cost actions and portfolio focus are translating into material profitability gains.
Free cash flow was negative in Q1 due to variable comp and transformation costs, but management expects a sharp improvement in Q2 and reaffirms full-year free cash flow guidance.
Executive Commentary
"We have done a lot of things, successfully executing on the product exits, divesting RH, making the DROS acquisition. and increasing our shareholdings through our repurchase program. I think we're established now the foundation to meet our midterm financial commitments, our transformation priorities, and shaping our portfolio, which we think are an attractive market."
Joe, CEO
"Our adjusted EBITDA grew by 34% compared to a year ago, with adjusted EBITDA margin expansion of 290 basis points. This margin expansion was positively impacted by top-line growth, manufacturing and operations execution, and continued SG&A optimization efforts."
Michael, CFO
Strategic Positioning
1. Digestive Health as Growth Engine
AVNS is doubling down on digestive health, leveraging innovation, targeted launches, and global expansion. Neomid’s double-digit growth highlights the payoff from NFIT conversion tailwinds, while management eyes continued above-market growth via new products and selective M&A. Portfolio rationalization is freeing resources for higher-return opportunities.
2. Pain Management Portfolio Reset
Pain management is in transition, with product exits and a new go-to-market strategy targeting low single-digit growth in 2024. Game Ready and RF ablation are gaining traction, while the Trident line (acquired via DROS) is outperforming expectations. The segment’s stabilization is essential for overall margin and growth targets.
3. Margin Expansion and Cost Discipline
Transformation initiatives are driving margin improvement, with gross margin nearing 60% and further upside expected in H2. SG&A optimization and manufacturing efficiencies are on track to deliver the targeted 38-39% SG&A ratio by 2025, supporting sustainable profit growth.
4. Capital Allocation and M&A Discipline
AVNS’s balance sheet flexibility is enabling opportunistic share repurchases and selective M&A, with management prioritizing bolt-ons in digestive health. Recent M&A discipline is evident, as the company passed on deals lacking sufficient growth or return potential.
5. Transformation Roadmap Execution
The company’s four transformation pillars—portfolio focus, commercial optimization, cost management, and capital allocation—are yielding measurable results, with management reaffirming 2024 and 2025 financial targets. Execution on these priorities remains the central narrative for investors.
Key Considerations
AVNS’s Q1 underscores the importance of disciplined portfolio management and operational execution in unlocking value. The quarter’s results reflect early wins from the transformation strategy, but also highlight areas still requiring attention, particularly in pain management and HA pricing volatility.
Key Considerations:
- Digestive Health Momentum: Continued innovation and NFIT adoption are critical to sustaining above-market growth.
- Pain Management Inflection: Execution on new product launches and ASC channel strategy will determine segment rebound.
- HA Portfolio Drag: Anticipated 20% revenue decline in HA is a known headwind, with stabilization expected by Q4.
- Transformation Consistency: Sustained margin and SG&A progress are essential to hitting 2025 targets.
- M&A Selectivity: Management’s disciplined approach to acquisitions should protect returns but may limit near-term inorganic growth.
Risks
Key risks include execution lapses in pain management turnaround, persistent pricing pressure in HA, and the need for consistent margin delivery to meet ambitious 2025 targets. Macroeconomic uncertainty and potential competitive responses in core categories could also impact growth. Transformation initiatives must deliver as planned, or valuation could reset if margin or growth targets slip.
Forward Outlook
For Q2 2024, AVNS guided to:
- Gross margin near 60%
- Free cash flow improvement versus Q1
For full-year 2024, management reaffirmed guidance:
- Revenue of $685 million to $705 million (mid-single-digit organic growth)
- Adjusted gross margin of 59.5% to 60.5%
- SG&A as a percentage of revenue at 41% to 42%
- Adjusted diluted EPS of $1.30 to $1.45
- Adjusted EBITDA margin improvement of at least 200 basis points
- Free cash flow of approximately $75 million
Management highlighted several factors that support the outlook:
- Digestive health momentum and new product launches in H2
- Stabilization and growth in pain management, excluding HA drag
Takeaways
AVNS’s Q1 demonstrates that transformation efforts are translating into real financial improvement, with digestive health growth and margin expansion leading the story.
- Portfolio Focus Delivers: Digestive health’s strong growth and pain management stabilization are validating the transformation strategy, though HA remains a drag.
- Margin and Cost Execution: Margin gains and SG&A leverage are tracking ahead, giving credibility to 2025 targets if sustained.
- Watch for Consistency: Investors should monitor pain management progress, HA stabilization, and transformation execution as key drivers of valuation and sentiment.
Conclusion
AVNS’s Q1 confirms that disciplined execution and portfolio focus are driving tangible improvements in growth and profitability. The company is on track with its transformation roadmap, but must continue to deliver in pain management and margin expansion to achieve its mid-term objectives.
Industry Read-Through
AVNS’s results highlight the importance of portfolio rationalization and operational discipline in medtech, especially for diversified device companies facing legacy product drag. The company’s margin expansion and cost control efforts set a benchmark for peers navigating similar transformation journeys. Digestive health’s outperformance underscores robust demand for enteral feeding and related solutions, while pain management’s uneven recovery signals that new product innovation and ASC channel execution are critical levers for growth across the sector. Competitors and investors should watch for margin trajectory and disciplined capital allocation as key differentiators in the evolving medtech landscape.